Company news

Novo Nordisk A/S news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novo Nordisk takes the field at the big game, putting Wegovy® pill in consumers' hands

February 6, 2026

Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers

February 5, 2026

Novo Nordisk files annual report with the SEC

February 4, 2026

Novo Nordisk initiates 2026 share repurchase programme

February 4, 2026

Novo Nordisk has published its annual report for 2025

February 4, 2026

Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025

February 3, 2026

Novo Nordisk releases 2026 sales and operating profit outlook

February 3, 2026

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial

February 2, 2026

New employee representative on the Board of Directors of Novo Nordisk A/S

January 31, 2026

US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy

January 27, 2026

Sesame Launches Wegovy® Pill Through Collaboration With Novo Nordisk

January 22, 2026

Novo Nordisk introduces "There's Only One Ozempic®" campaign, reuniting Justin Long and John Hodgman

January 20, 2026

Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes

January 20, 2026

Health Canada approves RYBELSUS® (semaglutide tablets) to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes

January 12, 2026

Novo Nordisk's GLP‑1 RA--A Modern Treatment for Obesity Management--is Linked to Lower Household Spending on Alcohol and Tobacco

January 12, 2026

Novo Nordisk International Operations Commits to Veeva Vault CRM

January 7, 2026

Emed provides access to FDA-approved Wegovy® pill through its trusted, clinically guided model of care

January 6, 2026

Novo Nordisk unveils the inaugural State of Weight and Health Report™, offering new insights that shed light on America's obesity epidemic

January 6, 2026

Novo Nordisk Launches Wegovy™ Pill, Expanding Patient Choice and Access With knownwell as a Recognized NovoCare® Provider

January 5, 2026

Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy® Pill Advancing a New Standard for Long-Term Weight Health

January 5, 2026

Ro launches Wegovy® pill through integration with NOVO Nordisk

January 5, 2026

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

January 5, 2026

Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent

December 31, 2025

Obesity Medicine Association Releases Position Statement: A New Era for Medicare & Medicaid Obesity Medication Coverage

December 24, 2025

FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults

December 22, 2025

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management

December 22, 2025

Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management

December 18, 2025

Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing

December 16, 2025

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss

December 12, 2025

Novo Nordisk has completed its acquisition of Akero Therapeutics

December 9, 2025

New Data from Semaglutide Trials Provides Critical Insights to Guide Next Generation of Therapies Targeting Alzheimer's Pathobiology

December 4, 2025

Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors

December 3, 2025

Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg

November 26, 2025

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes

November 25, 2025

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression

November 24, 2025

9amHealth to Expand Access to Obesity Management Treatment through New Employer Health Benefits Offering

November 21, 2025

Novo Nordisk launches introductory self-pay offer for Wegovy® and Ozempic® for $199 per month

November 17, 2025

Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S

November 14, 2025

Team Novo Nordisk announce extended partnership with Novo Nordisk for five additional years

November 14, 2025

Novo Nordisk A/S: Candidate for the Board of Directors will not seek election

November 13, 2025

Novo Nordisk's Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis

November 10, 2025

Novo Nordisk will not increase its proposal to acquire Metsera, Inc.

November 8, 2025

Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE

November 7, 2025

Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®

November 6, 2025

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost

November 6, 2025

Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications

November 5, 2025

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

November 5, 2025

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues

November 5, 2025

Novo Nordisk submits updated proposal to acquire Metsera, Inc.

November 4, 2025

Novo Nordisk Launches Wegovy® in Hong Kong for Weight Management

November 3, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 230 decks. Every deck is listed under its year.